Submission is based on extrapolation analysis and results examining the effects of Rexulti® (brexpiprazole) 2 to 4 mg/day in treating symptoms of schizophrenia in adolescent patients (13-17 years old).
Perspectives on how early interventions may help reduce deaths by suicide.
Thank you for subscribing to the Lundbeck Newsroom newsletter! We'll send the latest news and insights directly to your inbox.
You are about to leave the NewsRoom website and enter a website operated by an independent third party. The links to third-party websites are provided solely for your convenience. Lundbeck does not control the opinions, claims, or comments contained on any third-party website linked to NewsRoom.com, and your activities at those websites will be governed by the policies and practices of those third parties.
Select "OK" to proceed to this third-party website or "Cancel" to stay at NewsRoom.com.